DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) shares were up 5.2% on Monday . The company traded as high as $0.94 and last traded at $0.93. Approximately 675,578 shares traded hands during trading, a decline of 19% from the average daily volume of 838,291 shares. The stock had previously closed at $0.88.

A number of research analysts recently weighed in on DMPI shares. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of DelMar Pharmaceuticals in a report on Thursday. Maxim Group reaffirmed a “hold” rating on shares of DelMar Pharmaceuticals in a report on Monday, September 11th. Finally, Dawson James reaffirmed a “buy” rating on shares of DelMar Pharmaceuticals in a report on Tuesday, August 8th.

The firm has a 50-day moving average price of $1.11 and a 200 day moving average price of $2.10. The firm’s market cap is $20.04 million.

A hedge fund recently bought a new stake in DelMar Pharmaceuticals stock. Franklin Resources Inc. bought a new stake in DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,076,923 shares of the company’s stock, valued at approximately $2,477,000. 13.74% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This article was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at

About DelMar Pharmaceuticals

DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.

Receive News & Stock Ratings for DelMar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.